Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | -6.04% | Citigroup | $2 → $1.4 | Maintains | Sell |
| 08/09/2023 | 1577.85% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 06/14/2023 | 1779.19% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 05/09/2023 | 1242.28% | Canaccord Genuity | $50 → $20 | Maintains | Buy |
| 02/09/2023 | 1577.85% | EF Hutton | → $25 | Reiterates | → Buy |
| 02/09/2023 | 1712.08% | HC Wainwright & Co. | $29 → $27 | Maintains | Buy |
| 02/07/2023 | 1980.54% | Mizuho | → $31 | Reiterates | → Buy |
| 01/05/2023 | 1577.85% | EF Hutton | → $25 | Initiates Coverage On | → Buy |
| 08/16/2022 | 1980.54% | Mizuho | $39 → $31 | Maintains | Buy |
| 08/09/2022 | 101.34% | Goldman Sachs | $4 → $3 | Maintains | Sell |
| 07/20/2022 | 101.34% | Citigroup | → $3 | Downgrades | Neutral → Sell |
| 07/13/2022 | 571.14% | JP Morgan | → $10 | Downgrades | Overweight → Neutral |
| 07/13/2022 | 235.57% | Stifel | $16 → $5 | Downgrades | Buy → Hold |
| 05/24/2022 | 168.46% | Goldman Sachs | $5 → $4 | Maintains | Sell |
| 05/23/2022 | 1846.31% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 05/10/2022 | 436.91% | Citigroup | $23 → $8 | Downgrades | Buy → Neutral |
| 03/28/2022 | 1376.51% | JP Morgan | $27 → $22 | Maintains | Overweight |
| 01/03/2022 | 1712.08% | JP Morgan | $26 → $27 | Maintains | Overweight |
| 05/13/2021 | 1846.31% | JP Morgan | $23 → $29 | Upgrades | Neutral → Overweight |
| 05/05/2021 | 1980.54% | HC Wainwright & Co. | $32 → $31 | Maintains | Buy |
| 12/08/2020 | 1980.54% | HC Wainwright & Co. | $28 → $31 | Maintains | Buy |
| 11/10/2020 | 1779.19% | HC Wainwright & Co. | $26 → $28 | Maintains | Buy |
| 09/15/2020 | 5134.9% | Canaccord Genuity | $70 → $78 | Maintains | Buy |
| 08/06/2020 | 1779.19% | Stifel | $30 → $28 | Maintains | Buy |
| 08/06/2020 | 1644.97% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 06/30/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/15/2020 | 1577.85% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 05/12/2020 | 1443.62% | JP Morgan | $22 → $23 | Maintains | Neutral |
| 04/23/2020 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/08/2019 | 1376.51% | JP Morgan | $43 → $22 | Downgrades | Overweight → Neutral |
| 09/27/2019 | 504.03% | Goldman Sachs | $14 → $9 | Downgrades | Neutral → Sell |
| 09/16/2019 | 906.71% | Jefferies | $32 → $15 | Downgrades | Buy → Hold |
| 06/04/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 05/30/2019 | 1913.42% | Roth Capital | → $30 | Initiates Coverage On | → Buy |
| 05/23/2019 | 2651.68% | Stifel | → $41 | Initiates Coverage On | → Buy |
| 01/23/2019 | 4061.07% | Mizuho | → $62 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月21日 | -6.04% | 花旗集团 | $2→$1.4 | 维护 | 卖 |
| 08/09/2023 | 1577.85% | EF Hutton | →$25 | 重申 | 购买→购买 |
| 2023/06/14 | 1779.19% | HC Wainwright公司 | $27→$28 | 维护 | 买 |
| 05/09/2023 | 1242.28% | 卡纳科特·格纳奇 | $50→$20 | 维护 | 买 |
| 02/09/2023 | 1577.85% | EF Hutton | →$25 | 重申 | →购买 |
| 02/09/2023 | 1712.08% | HC Wainwright公司 | $29→$27 | 维护 | 买 |
| 02/07/2023 | 1980.54% | 瑞穗 | →$31 | 重申 | →购买 |
| 01/05/2023 | 1577.85% | EF Hutton | →$25 | 开始承保 | →购买 |
| 08/16/2022 | 1980.54% | 瑞穗 | $39→$31 | 维护 | 买 |
| 08/09/2022 | 101.34% | 高盛 | $4→$3 | 维护 | 卖 |
| 07/20/2022 | 101.34% | 花旗集团 | →$3 | 评级下调 | 中性→销售 |
| 07/13/2022 | 571.14% | 摩根大通 | →$10 | 评级下调 | 超重→中性 |
| 07/13/2022 | 235.57% | Stifel | $16→$5 | 评级下调 | 购买→Hold |
| 2022年05月24日 | 168.46% | 高盛 | $5→$4 | 维护 | 卖 |
| 2022年05月23日 | 1846.31% | HC Wainwright公司 | $31→$29 | 维护 | 买 |
| 2022年05月10日 | 436.91% | 花旗集团 | $23→$8 | 评级下调 | 购买→中性 |
| 03/28/2022 | 1376.51% | 摩根大通 | $27→$22 | 维护 | 超重 |
| 01/03/2022 | 1712.08% | 摩根大通 | $26→$27 | 维护 | 超重 |
| 2021/05/13 | 1846.31% | 摩根大通 | $23→$29 | 升级 | 中性→超重 |
| 05/05/2021 | 1980.54% | HC Wainwright公司 | $32→$31 | 维护 | 买 |
| 12/08/2020 | 1980.54% | HC Wainwright公司 | $28→$31 | 维护 | 买 |
| 11/10/2020 | 1779.19% | HC Wainwright公司 | $26→$28 | 维护 | 买 |
| 2020/09/15 | 5134.9% | 卡纳科特·格纳奇 | $70→$78 | 维护 | 买 |
| 08/06/2020 | 1779.19% | Stifel | $30→$28 | 维护 | 买 |
| 08/06/2020 | 1644.97% | HC Wainwright公司 | $25→$26 | 维护 | 买 |
| 06/30/2020 | - | Evercore ISI集团 | 开始承保 | →跑赢大盘 | |
| 2020/06/15 | 1577.85% | HC Wainwright公司 | →$25 | 开始承保 | →购买 |
| 2020/05/12 | 1443.62% | 摩根大通 | $22→$23 | 维护 | 中性 |
| 04/23/2020 | - | 花旗集团 | 升级 | 中性→购买 | |
| 2019年8月11日 | 1376.51% | 摩根大通 | $43→$22 | 评级下调 | 超重→中性 |
| 2019年09月27日 | 504.03% | 高盛 | $14→$9 | 评级下调 | 中性→销售 |
| 2019/09/16 | 906.71% | 杰富瑞 | $32→$15 | 评级下调 | 购买→Hold |
| 2019年04月06日 | - | 花旗集团 | 升级 | 卖出→中性 | |
| 2019年05月30日 | 1913.42% | 罗斯资本 | →$30 | 开始承保 | →购买 |
| 2019年05月23日 | 2651.68% | Stifel | →$41 | 开始承保 | →购买 |
| 2019年01月23日 | 4061.07% | 瑞穗 | →$62 | 开始承保 | →购买 |
What is the target price for Atara Biotherapeutics (ATRA)?
Atara BioTreateutics(ATRA)的目标价格是多少？
The latest price target for Atara Biotherapeutics (NASDAQ: ATRA) was reported by Citigroup on August 21, 2023. The analyst firm set a price target for $1.40 expecting ATRA to fall to within 12 months (a possible -6.04% downside). 8 analyst firms have reported ratings in the last year.
花旗集团于2023年8月21日报道了Atara BioTreatetics(纳斯达克：ATRA)的最新目标价。这家分析公司将目标价定为1.40美元，预计ATRA将在12个月内下跌(可能下跌6.04%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
Atara BioTreateutics(ATRA)的最新分析师评级是什么？
The latest analyst rating for Atara Biotherapeutics (NASDAQ: ATRA) was provided by Citigroup, and Atara Biotherapeutics maintained their sell rating.
Atara BioTreateutics(纳斯达克：ATRA)的最新分析师评级由花旗集团提供，Atara BioTreateutics维持卖出评级。
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Atara BioTreateutics(ATRA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Atara BioTreateutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Atara BioTreatetics的上一次评级是在2023年8月21日提交的，所以你应该预计下一次评级将在2024年8月21日左右的某个时候提供。
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
分析师对Atara BioTreateutics(ATRA)的评级正确吗？
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a maintained with a price target of $2.00 to $1.40. The current price Atara Biotherapeutics (ATRA) is trading at is $1.49, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Atara BioTreateutics(ATRA)评级保持不变，目标价在2.00美元至1.40美元之间。目前Atara BioTreateutics(ATRA)的交易价格为1.49美元，超出了分析师的预测区间。